Articles tagged with Tumor Growth
A study reveals that interleukin 34 (IL-34) modulates the balance between two myeloid-derived suppressor cell populations, leading to immunosuppression and chemoresistance in triple-negative breast cancer. Neutralizing IL-34 with a drug reduces tumor growth and susceptibility to chemotherapy.
A new method of modifying our immune system has been demonstrated in a study published in Advanced Science, which could help treat skin cancer.
In the ARROS-1 trial, 48% of patients achieved partial responses to NVL-520, with responses seen across all dose levels and in heavily pre-treated patients. The treatment also showed promise for brain metastases, with three out of three patients experiencing measurable response or no emergence of new metastases.
A new experimental drug has shown promising results in treating liver cancer, with two patients experiencing a partial response to the treatment. The drug, NMS-01940153E, targets an enzyme that plays a critical role in cell division and growth, and its side effects are manageable.
A new study reveals that urolithin A from pomegranates can rejuvenate T cells by recycling and renewing mitochondria, enhancing their ability to fight tumors. The researchers plan to investigate the application of urolithin A in clinical trials for colorectal cancer.
Researchers have found a drug that targets the key, cancer-causing gene MYC has been able to inhibit its function safely and effectively. Eight out of 12 patients showed stabilisation of disease after treatment with OMO-103, with one patient experiencing a reduction in tumour-derived DNA circulating in the blood stream.
Researchers discovered a molecular link between disrupted circadian rhythms and lung tumor growth, implicating a cancer-signature gene known as HSF1. Disrupted clocks may trigger lung tumors in individuals with irregular sleep patterns or night shifts.
A recent study by Weill Cornell Medicine investigators found that corrupted endothelial cells can protect leukemia cells from chemotherapy drugs. The discovery has the potential to improve drug discovery programs and clinical trials for T-cell acute lymphoblastic leukemia (T-ALL) patients.
Researchers at LSU Health New Orleans have identified a new drug target for triple-negative breast cancer, which lacks estrogen and progesterone receptors. The novel small molecule inhibitor NSC33353 works synergistically with doxorubicin to suppress the growth of TNBC cells.
Researchers at Mount Sinai's Tisch Cancer Institute have discovered a new gene, PDZK1IP1, essential to colon cancer growth. The study found that surrounding inflammation activates the super enhancer, promoting tumor cell survival and growth.
A large multi-center study analyzing patient records from three major cancer centers found that ILC is detected later and has worse outcomes than IDC. The research highlights the need for new imaging technologies to improve early detection of ILC, which often spreads beyond breast tissue before diagnosis.
The study reveals how the activating partner PI5P interacts with two different regions of regulatory protein UHRF1, showing its role in modulating complex proteins. This finding could breathe new life into the search for UHRF1-directed medicines.
A new study has uncovered a previously unknown genetic process that could inform the development of novel treatment options for glioblastoma (GBM), a virtually incurable brain tumor. The epidermal growth factor receptor (EGFR) signaling pathway and long non-coding RNA molecules, such as lncEPAT, play critical roles in GBM tumorigenesis.
A new epigenetics drug, tazemetostat, has been found to stop bladder cancer growth by activating the immune system, not just inhibiting tumors. The drug targets the EZH2 gene and is being tested in clinical trials for late-stage bladder cancer.
Researchers found that the quality and mix of collagen in pancreatic ductal adenocarcinoma tumors affects prognosis. Patients with tumors containing cleaved Collagen I experienced poor survival prospects, while those with non-cleaved Collagen I had better outcomes.
Researchers have developed a method to synthetically produce EBC-46, a cancer-fighting compound, using an abundant plant-based starting material. This breakthrough could lead to new treatments for various diseases, including AIDS and Alzheimer's disease.
Researchers developed a computational platform to identify metabolic vulnerabilities in ovarian cancer genes, suggesting opportunities for targeted therapies. The study found that certain genetic alterations can create vulnerabilities in cancer cell metabolism, which can be exploited to selectively kill cancer cells.
Researchers at the University of Helsinki have identified target genes of the MYC oncogene responsible for its growth-promoting effects. By modifying these genomic binding sites, they slowed down cell growth. This finding has significant implications for developing new cancer treatments.
Scientists successfully inhibited cancer cell growth using a modified pyrrolizidine alkaloid that avoids liver damage. The approach uses 'on-site synthesis' near cancer cells to limit toxicity.
A new biomarker called SPRIGHTLY could distinguish between two aggressive types of brain tumors in children: Group 3 and Group 4 medulloblastomas. The biomarker is highly expressed in Group 4 medulloblastomas, which have a poorer prognosis.
Researchers discovered a type of triple-negative breast cancer cell that can trigger dormancy, evading therapies and allowing for efficient survival in distant organs. This finding highlights the need for more selective therapeutic strategies targeting both dividing and invasive dormant cells.
A new study provides valuable insights into the roles of B cells and plasma cells in early-stage lung cancer biology, highlighting their influence on tumor development and treatment outcomes. The research also reveals environmental factors and molecular features that contribute to the landscape of infiltrating immune cells.
Researchers at Mayo Clinic Comprehensive Cancer Center found that metabolic imaging, combined with traditional treatment response assessment methods, can provide critical information to guide therapy for pancreatic cancer patients. The use of positron emission tomography (PET) with 18-fluorodeoxyglucose (FDG) tracer adds significant pr...
Researchers at Tel Aviv University develop a groundbreaking method to eradicate glioblastoma brain tumors by targeting astrocytes and starving them of energy. The study found that in the absence of these brain cells, tumor cells die and are eliminated, offering a promising basis for developing effective medications.
Researchers at the University of Gothenburg have identified a protein called HnRNPK that controls tumor growth by binding to messenger RNA, potentially enabling the development of new cancer drugs with fewer side effects.
Researchers at Karolinska Institutet have developed a potential curative treatment for neuroblastoma, using DHODH blockers in combination with chemotherapy to cure mice with the disease. The treatment has shown promising results and could improve survival rates for children with neuroblastoma.
Researchers at Kyoto University have developed a cancer therapy model that utilizes a protein degrading system to transiently degrade and reduce the PD-1 protein, which blocks immune function. This approach has shown high therapeutic efficacy in inhibiting cancer cell growth in mice.
A study found that cold temperatures activate brown adipose tissue that competes with tumors for glucose, inhibiting tumor growth and prolonging survival. Researchers suggest that cold therapy could be a promising approach to cancer therapy.
A new study by Tokyo University of Science researchers reveals that dendritic cell immunoreceptor (DCIR) plays a crucial role in the development of colorectal tumors. Blocking DCIR may prevent ulcerative colitis and colon cancer, offering a potential therapeutic target for treating these diseases.
A team of researchers has discovered that malignant tumors accumulate lipid delivery molecules called LDL and attract immune suppressor cells called neutrophils, leading to tumor progression. The study also shows that targeting the LOX-1/oxidized LDL axis may be a promising strategy for treating both cancer and cardiovascular disease.
Researchers have found that treating high-grade squamous intraepithelial lesions (HSILs) in people with HIV significantly decreases the progression to anal cancer. The ANCHOR trial enrolled over 4,000 participants and showed a 57% reduction in anal cancer cases.
Researchers discover G6PD's pivotal role in activating pentose phosphate pathway to counter oxidative stress, leading to increased cell death and tumor shrinkage. Ovarian cancer cells' reliance on fatty acid metabolism fuels oxidative compound production, which can be offset by G6PD inhibition.
A study by Michigan Medicine researchers has identified oncostreams, highly active cells connected to brain tumor growth and invasion. The team found that eliminating Collagen 1 production from tumor cells reduces tumor aggressive behavior. This discovery could lead to novel therapeutic targets for treating lethal brain tumors.
Researchers at Cold Spring Harbor Laboratory have discovered a way to regulate plant growth by manipulating proteins called UBP12 and UBP13, which helps control the amount of CRY2 photoreceptor in plants. This finding has potential applications in improving crop yields and informing cancer research.
Researchers from China have developed a novel bioconjugate that can suppress the growth of K-Ras mutant pancreatic tumors. The conjugate, which targets folate receptors and macropinocytosis, was found to be highly cytotoxic and effective at suppressing tumor growth.
Research describes how breast cancer cells impair pancreatic islet function to suppress insulin production, leading to diabetes and increased tumor growth. The study identifies microRNA-122 as a key player in this process.
Researchers have identified a previously unrecognized form of hormone therapy-resistant prostate cancer and found promising drug targets to treat it. The discovery opens the door to developing therapies that specifically target this disease, which accounts for approximately a quarter of castration-resistant prostate cancers.
A new interactive web portal, SpUR, catalogues over 1,000 splicing events found in cancers, highlighting their role in tumor development and progression. The database provides a platform for researchers to study RNA dysregulations in cancer and develop RNA-based anti-cancer drugs.
Scientists have discovered a small molecule that bypasses ADAR1 suppression and directly activates tumor cell death by ZBP1, inducing highly immunogenic cell death and destroying fibroblasts supporting tumor growth. This approach has the potential to improve the effectiveness of immunotherapy in treating therapy-resistant tumors.
A new study found that crown-like structures surrounding breast tumors in overweight and obese patients can hinder their response to therapy. Researchers identified a potential molecular biomarker, CD32B, which is associated with poorer treatment outcomes.
Researchers have developed biodegradable nanovesicles that efficiently encapsulate and deliver PARP1 siRNA to breast cancer tumors in mice, inhibiting oncogene expression and extending survival. The polymersomes, assembled from three biodegradable block copolymers, have strong potential for precision-targeted therapeutic carriers.
A Brazilian group developed a peptide called Rb4 that triggers necrosis in murine melanoma cells and inhibits the viability of human cancer cells. In mice, Rb4 reduced lung metastasis and slowed subcutaneous melanoma growth, increasing survival by 25%.
Researchers at Ohio State University Wexner Medical Center have discovered a new molecular drug target to treat cancer, VEGF-A, which can increase expression of dopamine D2 receptors on endothelial cells to stop blood vessel growth and spread diseases like colon cancer and ovarian hyperstimulation syndrome.
Researchers discovered that neurons carrying a mutation in the Nf1 gene are hyperexcitable and suppressing this hyperactivity with lamotrigine stops tumor growth in mice. The study provides an explanation for why some people with NF1 lack optic gliomas or neurofibromas, highlighting the critical role of neurons in tumor biology.
A UC Davis study found a critical agent keeping KSHV dormant and undetected by the immune system. The virus is linked to various cancers and AIDS-related diseases. The researchers identified CHD4 as a key regulator of the latency-lytic switch, allowing the virus to stay silent.
A new drug called abemaciclib has been shown to halt the growth of recurring brain tumors in patients with aggressive meningiomas. The treatment targets a common molecular pathway that enables cells to divide rapidly and come back after surgery, allowing researchers to predict recurrence more accurately.
Researchers found that genetic mutations in the MAPK pathway, key to normal cell growth, can also make head and neck cancer vulnerable. Individualized genomic analysis can identify specific mutations and target drugs, offering a promising approach to precision medicine.
The University at Buffalo is developing new treatments for ovarian cancer by targeting the apelin receptor. Ovarian cancer cells rely on lipids for energy and survival, making this a promising therapeutic target.
Researchers at Case Western Reserve University discovered that altering macrophage metabolism influences their relationship with T cells, suppressing tumor growth and reducing overall tumor size. The study found PERK protein's involvement in key metabolic pathways and identified a potential clinical drug inhibitor to target it.
Researchers have found that treating prostate cancer cells with novel CDK8 and CDK19 inhibitors reduces their potential to migrate into surrounding structures. This suggests a promising approach to overcome resistance against anti-androgenic therapy, offering new therapeutic options for patients with advanced disease.
Researchers have discovered a potential new treatment for glioblastoma, which targets 'kinase' proteins to limit tumour growth and improve existing chemotherapeutic drugs. This breakthrough therapy may provide hope for patients with aggressive brain tumours, offering a more effective and sustainable approach to treatment.
A study by MedUni Vienna reveals that mutations in the KMT2C protein lead to increased cell division, driving metastatic prostate cancer. This discovery may enable early diagnosis through a blood test and treatment with MYC inhibitors.
Researchers have discovered two distinct classes of cancer-associated fibroblasts that accumulate in the pancreatic tumor microenvironment and play opposing roles. The study suggests that targeting these unique cell populations may improve treatment outcomes for pancreatic cancer patients.
Researchers at Karolinska Institutet identified a novel protein mechanism that inhibits tumour growth in ER-negative breast cancer, leading to improved prognosis. High levels of GIT1 were associated with reduced tumour growth and better outcomes in ER-negative patients.
Researchers developed a novel genetic barcode system to mark cancer cells with different gene modifications and image their characteristics. The Perturb-map platform identified specific genes controlling lung tumor growth, immune composition, and response to immunotherapy, offering new approaches for targeting anti-cancer drugs.
Researchers at Massachusetts General Hospital found that using nanomedicines at lower, more frequent doses can normalize the tumor microenvironment and improve cancer treatments. The study showed that this approach can help correct abnormalities that protect tumors and improve blood vessel function and immune activation within a tumor.
Researchers found that the Klotho gene can suppress glioblastoma cell viability and induce apoptosis, leading to a significant decrease in tumor growth. The study contributes to the development of new diagnostic and treatment approaches for malignant brain tumors.
A team from UNIGE has identified a potential target for restoring the efficacy of standard breast cancer treatment. The loss of SPRED2 protein leads to tumor proliferation even with tamoxifen treatment. Combining tamoxifen with an inhibitor of estrogen-independent cell activation may be promising for resistant patients.
Researchers at UCSF develop a new cancer treatment that targets RAS-mutated tumors by exploiting their high levels of ferrous iron. The treatment, TRX-cobimetinib, is more effective and tolerable than current treatments like cobimetinib, which can cause serious side effects in normal tissues.
Researchers at Tokyo University of Science have developed bionanoparticles derived from corn that selectively target and inhibit the growth of cancer cells, inducing tumor necrosis factor-α release. These findings suggest a novel, economical, and safe anti-cancer therapy approach.